Research programme: immune checkpoint modulators - Apeiron Biologics/Lead Discovery Center
Latest Information Update: 14 Mar 2025
At a glance
- Originator Apeiron Biologics; The Lead Discovery Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer